98%
921
2 minutes
20
Background: Sexually transmitted infections (STIs) are a common reason for evaluation in the emergency department (ED). Given the overlapping risk factors for STIs, patients screened for gonorrhea and chlamydia should be tested for syphilis and HIV. Syphilis and HIV testing rates in the ED have been reported to be low. The study objective was to examine whether collaboration between emergency medicine (EM) and infectious disease (ID) providers improved syphilis and HIV testing in the ED.
Methods: A multidisciplinary team of EM and ID providers was formed to identify and address barriers to syphilis and HIV testing in the ED. Syphilis, HIV, chlamydia, and gonorrhea testing and infection rates were calculated and compared during 2 time periods: preintervention (January 1, 2012-December 30, 2017) and postintervention (November 1, 2018-November 30, 2019). We also extracted clinical and laboratory data from patients with positive syphilis and HIV results during the study period.
Results: The most commonly cited barrier to syphilis and HIV testing was concern about follow-up of positive results. Compared with the preintervention period, syphilis and HIV testing rates increased significantly in the postintervention period (incidence rate ratios, 30.70 [P < 0.0001] and 28.99 [P < 0.0001] for syphilis and HIV, respectively). The postintervention period was also associated with a significant increase in the identification of patients with positive syphilis and HIV results (incidence rate ratios, 7.02 [P < 0.0001] and 2.34 [P = 0.03], respectively).
Conclusions: Collaboration between EM and ID providers resulted in a significant increase in syphilis and HIV testing and diagnosis in the ED.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8663525 | PMC |
http://dx.doi.org/10.1097/OLQ.0000000000001496 | DOI Listing |
Sex Transm Dis
September 2025
Departments of Global Health, Medicine, and Epidemiology, University of Washington (JN Wasserheit), National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention (J Mermin and BP Stoner), and Rietmeijer Consulting (CA Rietmeijer).
Transfusion
September 2025
Medical Affairs and Innovation, Canadian Blood Services, Ottawa, Ontario, Canada.
Introduction: Donors are deferred if they are on antiretroviral medications (ARV) as post-exposure or pre-exposure prophylaxis (PEP or PrEP) for human immunodeficiency virus (HIV). We assessed donor compliance by measuring ARV levels in selected anonymized donor samples collected from September 22, 2022 to December 31, 2024, almost all after the introduction of sexual risk behavior screening.
Methods: EDTA plasma samples collected at the time of donation (retention samples) were retrieved, frozen, and shipped for measurement of tenofovir and emtricitabine.
medRxiv
August 2025
Infectious Diseases Institute, Makerere University, Kampala, Uganda.
Introduction: In Uganda, the spatial distribution of syphilis varies by age, gender, and region. Identifying clusters (subsets of administrative subdivisions) with high syphilis prevalence could boost efforts to eliminate mother-to-child transmission of syphilis. We examined spatial variations and clustering of syphilis prevalence among pregnant young women in Central Uganda.
View Article and Find Full Text PDFOpen Forum Infect Dis
September 2025
Division of Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: The correlation between human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) usage and sexually transmitted infections (STIs) remains equivocal. Limited studies have investigated national STI trends after introducing PrEP. We aimed to examine STI incidence before and after PrEP introduction and explore correlations with PrEP use in the United States.
View Article and Find Full Text PDFBMJ Open
September 2025
Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaounde, Cameroon.
Objective: The study was conducted to assess the diagnostic performance of the Hightop Syphilis Rapid Diagnostic Test (RDT) in comparison with the ELISA test used as a reference method.
Design: A laboratory-based cross-sectional and comparative study was conducted to assess the diagnostic performance of the Hightop Syphilis RDT.
Setting: Blood samples obtained from adult participants in eight health facilities were analysed at the National Public Health Laboratory (NPHL), Ministry of Public Health, Yaounde, Cameroon.